Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Francis Crick Institute
Research
Who might better benefit from KRAS and PD-1 combos?
A new study suggests that immune "hot" tumors are more likely to respond to KRAS/PD-1 combinations.
Angus Liu
Jul 26, 2022 3:30am
Enzyme inhibitor could counter leukemia's 'bad seeds'
Jun 22, 2022 2:00pm
Stem cell defense against RNA viruses could inspire COVID R&D
Jul 8, 2021 2:00pm
Pan-cancer genome sequencing reveals new treatment targets
Feb 5, 2020 1:00pm
Shutting down cancer cell 'highways' by blocking a protein
Oct 29, 2019 8:14am
Boosting KRAS inhibitors in lung cancer with a combo
Sep 18, 2019 2:00pm
